DE602005023976D1 - Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion - Google Patents
Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktionInfo
- Publication number
- DE602005023976D1 DE602005023976D1 DE602005023976T DE602005023976T DE602005023976D1 DE 602005023976 D1 DE602005023976 D1 DE 602005023976D1 DE 602005023976 T DE602005023976 T DE 602005023976T DE 602005023976 T DE602005023976 T DE 602005023976T DE 602005023976 D1 DE602005023976 D1 DE 602005023976D1
- Authority
- DE
- Germany
- Prior art keywords
- amyloid
- gpcr
- compositions
- beta
- amyloid beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 abstract 2
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 238000000423 cell based assay Methods 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000020978 protein processing Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56366104P | 2004-04-20 | 2004-04-20 | |
| PCT/EP2005/004325 WO2005103713A2 (en) | 2004-04-20 | 2005-04-20 | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602005023976D1 true DE602005023976D1 (de) | 2010-11-18 |
Family
ID=35197590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005023976T Expired - Lifetime DE602005023976D1 (de) | 2004-04-20 | 2005-04-20 | Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7429459B2 (https=) |
| EP (3) | EP2270513A3 (https=) |
| JP (1) | JP4890442B2 (https=) |
| AT (1) | ATE483981T1 (https=) |
| CA (1) | CA2605574A1 (https=) |
| DE (1) | DE602005023976D1 (https=) |
| DK (1) | DK1745295T3 (https=) |
| ES (1) | ES2353604T3 (https=) |
| SI (1) | SI1745295T1 (https=) |
| WO (1) | WO2005103713A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005103713A2 (en) * | 2004-04-20 | 2005-11-03 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| JP5421109B2 (ja) * | 2006-09-13 | 2014-02-19 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 低カルボキシル化／非カルボキシル化オステオカルシンはベータ細胞増殖、インスリン分泌、インスリン感受性、耐糖能を増加させ、体脂肪量を減少させる |
| GB0700645D0 (en) * | 2007-01-12 | 2007-02-21 | Eisai London Res Lab Ltd | Targets for disease therapy |
| KR20100029079A (ko) * | 2007-05-15 | 2010-03-15 | 헬리콘 테라퓨틱스 인코퍼레이티드 | Ｇｐｒ12의 저해로 인지 질환을 치료하는 방법 |
| JP2010527243A (ja) * | 2007-05-15 | 2010-08-12 | ヘリコン セラピューティクス，インコーポレイテッド | 低分子干渉ＲＮＡ（ｓｉＲＮＡ）を用いた記憶形成に関わる遺伝子の同定方法 |
| JP5049713B2 (ja) * | 2007-09-14 | 2012-10-17 | 株式会社コナミデジタルエンタテインメント | ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置 |
| EP2440934B1 (en) | 2009-06-08 | 2014-07-16 | Vib Vzw | Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation |
| WO2011102901A1 (en) * | 2010-02-20 | 2011-08-25 | Ebiotec (Euroespes Biotechnology) | Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphingosine-1-phosphate |
| US20130331330A1 (en) * | 2012-06-08 | 2013-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase |
| US20150065376A1 (en) * | 2013-08-12 | 2015-03-05 | Holger Knaut | Expression constructs encoding g protein coupled receptors and methods of use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US6090575A (en) | 1995-03-30 | 2000-07-18 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein coupled receptor GPR1 |
| WO1996030406A1 (en) | 1995-03-30 | 1996-10-03 | Human Genome Sciences, Inc. | Human g-protein coupled receptors |
| US5998164A (en) | 1995-03-30 | 1999-12-07 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein coupled receptor GPRZ |
| US6653086B1 (en) | 1998-04-14 | 2003-11-25 | Arena Pharmaceuticals, Inc. | Endogenous constitutively activated G protein-coupled orphan receptors |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| US6420563B1 (en) | 1998-07-31 | 2002-07-16 | Arena Pharmaceuticals, Inc. | Small molecule modulators of G protein-coupled receptor six |
| AU6453501A (en) | 1999-02-26 | 2001-09-03 | Arena Pharmaceuticals, Inc. | Small molecule modulators of G protein-coupled receptor six |
| WO2001048483A2 (en) * | 1999-12-10 | 2001-07-05 | Astrazeneca Ab | Method for screening of appetite control agents |
| WO2001084158A1 (en) * | 2000-05-03 | 2001-11-08 | Astrazeneca Ab | Use of the g protein coupled receptor gpr3 to identify appetite control agents |
| WO2001090128A2 (en) * | 2000-05-24 | 2001-11-29 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the gpr3 gene |
| US7163800B2 (en) | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
| WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| AU2002255478A1 (en) | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| US20050118639A1 (en) * | 2002-02-22 | 2005-06-02 | Takeda Chemical Industries, Ltd | Method of determining ligand |
| WO2003097795A2 (en) * | 2002-05-13 | 2003-11-27 | Norak Biosciences, Inc. | Constitutively translocating cell line |
| JP4184875B2 (ja) * | 2002-06-14 | 2008-11-19 | 武田薬品工業株式会社 | 新規スクリーニング方法 |
| US20040023380A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 6 expression |
| US20040023384A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 12 expression |
| WO2004038407A2 (en) * | 2002-10-24 | 2004-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) |
| WO2004042405A2 (en) | 2002-11-04 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3) |
| WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| CA2539127A1 (en) * | 2003-09-19 | 2005-03-31 | Paradigm Therapeutics Limited | Receptor |
| WO2005103713A2 (en) * | 2004-04-20 | 2005-11-03 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
-
2005
- 2005-04-20 WO PCT/EP2005/004325 patent/WO2005103713A2/en not_active Ceased
- 2005-04-20 ES ES05744241T patent/ES2353604T3/es not_active Expired - Lifetime
- 2005-04-20 US US11/110,274 patent/US7429459B2/en not_active Expired - Fee Related
- 2005-04-20 DK DK05744241.0T patent/DK1745295T3/da active
- 2005-04-20 CA CA002605574A patent/CA2605574A1/en not_active Abandoned
- 2005-04-20 EP EP10174529A patent/EP2270513A3/en not_active Withdrawn
- 2005-04-20 SI SI200531166T patent/SI1745295T1/sl unknown
- 2005-04-20 EP EP10174532A patent/EP2267458A3/en not_active Withdrawn
- 2005-04-20 EP EP05744241A patent/EP1745295B1/en not_active Expired - Lifetime
- 2005-04-20 JP JP2007508855A patent/JP4890442B2/ja not_active Expired - Fee Related
- 2005-04-20 AT AT05744241T patent/ATE483981T1/de active
- 2005-04-20 DE DE602005023976T patent/DE602005023976D1/de not_active Expired - Lifetime
-
2008
- 2008-08-13 US US12/190,888 patent/US7910320B2/en not_active Expired - Fee Related
-
2011
- 2011-02-01 US US13/019,057 patent/US20110118338A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1745295B1 (en) | 2010-10-06 |
| EP2267458A3 (en) | 2011-04-06 |
| WO2005103713A2 (en) | 2005-11-03 |
| US20110118338A1 (en) | 2011-05-19 |
| US7910320B2 (en) | 2011-03-22 |
| US20050266502A1 (en) | 2005-12-01 |
| CA2605574A1 (en) | 2005-11-03 |
| DK1745295T3 (da) | 2011-01-31 |
| ATE483981T1 (de) | 2010-10-15 |
| EP1745295A2 (en) | 2007-01-24 |
| EP2270513A3 (en) | 2011-04-06 |
| WO2005103713A3 (en) | 2006-09-08 |
| SI1745295T1 (sl) | 2011-01-31 |
| ES2353604T3 (es) | 2011-03-03 |
| EP2270513A2 (en) | 2011-01-05 |
| HK1099810A1 (en) | 2007-08-24 |
| JP4890442B2 (ja) | 2012-03-07 |
| JP2007533989A (ja) | 2007-11-22 |
| US7429459B2 (en) | 2008-09-30 |
| EP2267458A2 (en) | 2010-12-29 |
| US20090005262A1 (en) | 2009-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005108949A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| BRPI1007867B8 (pt) | anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente | |
| JP2014506244A5 (https=) | ||
| ATE483981T1 (de) | Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion | |
| US20170037472A1 (en) | Methods for the treatment of kidney fibrosis | |
| DE602006006855D1 (de) | Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb) | |
| Xin et al. | Proteomics study reveals that the dysregulation of focal adhesion and ribosome contribute to early pregnancy loss | |
| ATE487141T1 (de) | Hemmung von gasc1 | |
| EA201491411A1 (ru) | Растворимый manf при поражениях бета-клеток поджелудочной железы | |
| ATE468535T1 (de) | Verwendung von nnmt als marker für lungenkrebs | |
| DE602004017884D1 (de) | Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren | |
| WO2005119262A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| ATE462803T1 (de) | Kit und verfahren zum nachweis von urothelkarzinom | |
| ATE410696T1 (de) | Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis | |
| DE602004017317D1 (de) | Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome | |
| WO2005103693A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| RU2013158623A (ru) | Способ идентификации лигандов для белков, агрегированных в бета-листы | |
| WO2005103692A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| WO2005103715A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
| ATE353544T1 (de) | Verwendung des proteins masp als marker für kolorektale karzinome | |
| DE602004005859D1 (de) | Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs | |
| US20110318770A1 (en) | Compositions, kits and methods for determining plasmin activity | |
| KR101515211B1 (ko) | 간 섬유화 진단용 바이오마커 HtrA2 | |
| ATE519114T1 (de) | Verfahren zur identifizierung neuer leitverbindungen für arzneistoffkandidaten | |
| ATE455305T1 (de) | Verfahren zur bestimmung des verhältnisses von zwei verschiedenen peptiden oder polynukleinsäuren |